Aciclovir - Astrapharm (acyclovir) 200mg 20 tablets — Made in Ukraine — Free Delivery

Pharmacotherapeutic group

Antiviral agents for systemic use. antiviral agents of direct action. nucleosides and nucleotides, excluding reverse transcriptase inhibitors. acyclovir.

Clinical characteristics

Indications

Treatment of viral infections of the skin and mucous membranes caused by the herpes simplex virus, including primary and recurrent genital herpes. suppression (prevention of recurrence) of infections caused by the herpes simplex virus in patients with normal immunity. prevention of infections caused by the herpes simplex virus in patients with immunodeficiency. treatment of infections caused by the varicella zoster virus (chickenpox and herpes zoster).

Contraindications

Hypersensitivity to acyclovir, valacyclovir or other components of the preparation.

Method of administration and dosage

The tablet should be taken whole with water. when using high doses of acyclovir, an adequate level of body hydration should be maintained.

Adults

Treating herpes simplex virus infections

For the treatment of infections caused by the herpes simplex virus, it is necessary to take Acyclovir-Astrafarm tablets at a dose of 200 mg 5 times a day at approximately 4-hour intervals, with the exception of the night period.

Treatment should be continued for 5 days, but in the case of a severe primary infection, it can be continued.

For patients with severe immunodeficiency (for example, after bone marrow transplantation) or for patients with reduced absorption in the intestine, the dose can be doubled to 400 mg or the dosage form of the preparation can be used for intravenous administration.

Treatment should be started as early as possible after the onset of the infection. In the case of recurrent herpes, it is best to start treatment during the prodromal period or after the first signs of skin lesions appear.

Prevention of relapse (suppressive therapy) of herpes simplex virus infections

For patients with normal immunity, to prevent recurrence of infections caused by the herpes simplex virus, Acyclovir-Astrafarm tablets are prescribed at a dose of 200 mg 4 times a day with a 6-hour interval.

For convenience, most patients can take 400 mg twice daily at 12-hour intervals.

The treatment will be effective even after reducing the dose of the tablet preparation Acyclovir-Astrafarm to 200 mg, which is taken 3 times a day with an 8-hour interval or even 2 times a day with a 12-hour interval.

In some patients, a radical improvement is noted after taking a daily dose of Acyclovir-Astrafarm 800 mg.

To monitor possible changes in the natural course of the disease, acyclovir therapy should be interrupted periodically at intervals of 6-12 months.

Prevention of herpes simplex virus infections

For the prevention of infections caused by the herpes simplex virus, patients with immunodeficiency should take tablets of the preparation Acyclovir-Astrafarm in a dose of 200 mg 4 times a day with a 6-hour interval. For patients with significant immunodeficiency (for example, after bone marrow transplantation) or for patients with reduced absorption in the intestine, the dose can be doubled to 400 mg or the corresponding dose can be used for intravenous administration.

The duration of prophylaxis depends on the length of the risk period.

Treatment for chickenpox and herpes zoster

For the treatment of infections caused by the viruses of chickenpox and herpes zoster, take Acyclovir-Astrafarm tablets at a dose of 800 mg 5 times a day at 4-hour intervals, with the exception of the night period. Treatment should continue for 7 days.

Patients with severe immunodeficiency (for example, after bone marrow transplantation) or patients with reduced absorption in the intestine are best used in / in the introduction.

Treatment should be started as early as possible after the onset of the disease, the result will be better if treatment is started immediately after the onset of the rash.

Children

For the treatment and prevention of infections caused by the herpes simplex virus in children with immunodeficiency from 2 years of age, doses can be used as for adults.

For the treatment of chickenpox in children from the age of 6 years, 800 mg of acyclovir is prescribed 4 times a day, children aged 2 to 6 years can receive 400 mg of acyclovir 4 times a day. The duration of treatment is 5 days.

More precisely, the dose can be calculated by the child's body weight - 20 mg / kg of body weight per day (not to exceed 800 mg), which is divided into 4 doses.

There are no special data on the use of acyclovir for the prevention (prevention of recurrence) of infections caused by the herpes simplex virus, or for the treatment of infections caused by the herpes zoster virus, in children with normal immunity.

Children under 2 years of age do not use this dosage form of the preparation.

Elderly patients

It should be borne in mind the possibility of impaired renal function in elderly patients, and the dose of the preparation for them should be changed accordingly (see Renal failure). It is necessary to maintain an adequate level of hydration of the body.

Renal failure

Acyclovir should be used with caution in patients with renal insufficiency. It is necessary to maintain an adequate level of hydration of the body.

In the prevention and treatment of infections caused by the herpes simplex virus in patients with renal insufficiency, the recommended oral doses do not lead to the accumulation of acyclovir, the level of which would exceed the safe limit established for IV administration. However, for patients with severe renal impairment (creatinine clearance

In the treatment of infections caused by the Varicella zoster virus (chickenpox and herpes zoster), for patients with significantly reduced immunity, it is recommended for severe renal failure (creatinine clearance)

Adverse Reactions

Blood disorders: anemia, thrombocytopenia, leukopenia.

From the immune system: anaphylaxis.

From the nervous system: headache, dizziness, agitation, confusion, tremor, ataxia, dysarthria, hallucinations, psychotic symptoms, convulsions, drowsiness, encephalopathy, coma.

The above neurological reactions are generally reversible and usually occur in patients with renal insufficiency or other risk factors.

From the respiratory system: shortness of breath.

From the digestive system: nausea, vomiting, diarrhea, abdominal pain.

From the hepatobiliary system: a reversible increase in the level of bilirubin and liver enzymes, jaundice, hepatitis.

On the part of the skin: itching, rash (including photosensitivity), urticaria, accelerated diffuse hair loss (since hair loss can be associated with a large number of diseases and preparations, a clear connection with acyclovir has not been identified); angioedema.

On the part of the kidneys and urinary system: increased levels of urea and blood creatinine, acute renal failure, pain in the kidneys. Kidney pain can be associated with renal failure and crystalluria.

General disorders: increased fatigue, fever.

Overdose

Symptoms: Accidental repeated overdose of oral acyclovir over several days causes gastroenterological (such as nausea and vomiting) and neurological symptoms (headache and confusion).

Overdose neurological manifestations can be confusion, hallucinations, agitation, convulsions, and coma.

Treatment: the patient must be carefully examined to identify symptoms of intoxication. Gastric lavage is recommended. Treatment is symptomatic. Since the level of acyclovir in the blood is well excreted by hemodialysis, it should be used in case of overdose.

Application features

Use during pregnancy and lactation.

There was no increase in the number of congenital defects in children whose mothers used acyclovir during pregnancy. However, acyclovir tablets should be used when the potential benefit of the preparation to the mother outweighs the possible risk to the fetus.

When taken orally 200 mg 5 times a day, acyclovir passes into breast milk. Therefore, prescribing acyclovir for breastfeeding should be done with caution, taking into account the risk / benefit ratio.

Children.

The preparation in this dosage form is not prescribed for children under 2 years of age.

Acyclovir is excreted from the body mainly by renal clearance, therefore, the dose should be reduced in patients with renal insufficiency (see "Dosage and Administration"). Elderly patients are also more likely to have impaired renal function, therefore, a dose reduction may also be required for this group of patients. Both of these groups (patients with renal failure and elderly patients) are at risk of neurological side effects and therefore should be closely monitored to identify these side effects. According to the obtained data, such reactions are reversible in case of discontinuation of treatment.

Particular attention should be paid to maintaining an adequate level of hydration in patients receiving high doses of acyclovir.

The preparation contains lactose, so it should not be used in patients with moderate hereditary forms of galactose intolerance, congenital lactase deficiency or glucose-galactose malabsorption syndrome.

The ability to influence the reaction rate when driving or working with other mechanisms.

When deciding on the possibility of driving vehicles and other mechanisms, the clinical status of the patient and the profile of side effects of the preparation should be taken into account. Clinical studies of the effect of acyclovir on the reaction rate when driving or working with other mechanisms have not been conducted. In addition, the pharmacology of acyclovir does not give reason to expect any negative effects.

Interaction with other medicinal products and other types of interactions

No clinically important interactions of acyclovir with other preparations have been identified.

Acyclovir is excreted mainly unchanged by the kidneys by tubular secretion, so any preparations that have a similar release mechanism can increase the concentration of acyclovir in the blood plasma. Probenecid and cimetidine prolong the half-life of acyclovir and the area under the concentration / time curve. With simultaneous use with immunosuppressants in the treatment of patients after organ transplantation, the level of acyclovir and the inactive metabolite of the immunosuppressive preparation also increases in the blood plasma, but given the broad therapeutic index of acyclovir, there is no need to adjust the dose.

Pharmaceutical characteristics

Basic physical and chemical properties: tablets of white or almost white color, round, biconvex and with a notch on one side.

Shelf life

5 years.

Storage conditions

Store in its original packaging at a temperature not exceeding 25 ° C.

Keep out of the reach of children.